Tag: PN6047
PharmNovo reports broader therapeutic potential for PN6047
PharmNovo AB has announces new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the...
PharmNovo secures CTA approval in Spain
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...
PharmNovo’s CTA submission for lead candidate PN6047
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...
PharmNovo gets positive FDA feedback for neuropathic pain pain
PharmNovo, a Swedish clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain, has announced that it has received positive and...
PharmNovo awarded blended funding of €17.5M from EIC
PharmNovo, a Swedish clinical-stage pharmaceutical company, has been awarded €17.5 M in blended funding from the European Innovation Council (EIC) Accelerator under the Horizon...
PharmNovo scores in neuropathic pain management
Swedish pharmaceutical company PharmNovo has announced the positive final results from the Phase I trial of its neuropathic pain drug candidate, PN6047. This trial...
PharmNovo’s phase IIa study of PN6047 in neuropathic pain
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatments, has announced its collaboration with Worldwide Clinical Trials, a full-service contract research organization (CRO), to...
PharmNovo’s preclinical results on opioid receptor
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatment, has announced promising preclinical results for drug candidate PN6047. It is a new type of...